Bio-Techne Stock Forecast, Price & News

Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

Is Bio-Techne a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Techne?

Wall Street analysts have given Bio-Techne a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Techne wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bio-Techne?

Bio-Techne saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 406,000 shares, a decrease of 23.8% from the August 31st total of 532,700 shares. Based on an average trading volume of 335,600 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.1% of the shares of the company are sold short.
View Bio-Techne's Short Interest.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Bio-Techne.

How can I listen to Bio-Techne's earnings call?

Bio-Techne will be holding an earnings conference call on Tuesday, November 2nd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13724007".

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported $1.87 earnings per share for the quarter, beating analysts' consensus estimates of $1.47 by $0.40. The biotechnology company earned $259.03 million during the quarter, compared to analyst estimates of $247 million. Bio-Techne had a net margin of 15.08% and a trailing twelve-month return on equity of 15.19%.
View Bio-Techne's earnings history.

How has Bio-Techne's stock price been impacted by COVID-19 (Coronavirus)?

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TECH stock has increased by 175.5% and is now trading at $497.45.
View which stocks have been most impacted by COVID-19.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Thursday, August 5th. Shareholders of record on Monday, August 16th will be paid a dividend of $0.32 per share on Friday, August 27th. This represents a $1.28 annualized dividend and a dividend yield of 0.26%. The ex-dividend date is Friday, August 13th.
View Bio-Techne's dividend history.

Is Bio-Techne a good dividend stock?

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.25%. Bio-Techne does not yet have a strong track record of dividend growth. The dividend payout ratio of Bio-Techne is 22.34%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.26% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

What price target have analysts set for TECH?

9 equities research analysts have issued 12-month target prices for Bio-Techne's shares. Their forecasts range from $340.00 to $540.00. On average, they anticipate Bio-Techne's stock price to reach $458.00 in the next twelve months. This suggests that the stock has a possible downside of 7.9%.
View analysts' price targets for Bio-Techne or view top-rated stocks among Wall Street analysts.

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:

• Charles R. Kummeth, President, Chief Executive Officer & Director
• James T. Hippel, CFO & Principal Accounting Officer
• Robert Monroe, Chief Medical Officer
• Brenda Swierenga Furlow, Secretary & Chief Compliance Officer
• Robert M. Gavin, Vice President-Corporate Development

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

Who are some of Bio-Techne's key competitors?

Some companies that are related to Bio-Techne include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), Charles River Laboratories International (CRL), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of TECH's competitors.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and The Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Obermeyer Wood Investment Counsel Lllp (0.25%), Robeco Institutional Asset Management B.V. (0.12%), Chevy Chase Trust Holdings Inc. (0.06%), RMB Capital Management LLC (0.05%), State of Alaska Department of Revenue (0.05%) and Oregon Public Employees Retirement Fund (0.03%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne.

Which institutional investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Louisiana State Employees Retirement System, New Mexico Educational Retirement Board, State of Alaska Department of Revenue, Pacer Advisors Inc., Exchange Traded Concepts LLC, RMB Capital Management LLC, and Tributary Capital Management LLC. Company insiders that have sold Bio-Techne company stock in the last year include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Glenn Hedde, James Hippel, Kim Kelderman, Norman David Eansor, and Roeland Nusse.
View insider buying and selling activity for Bio-Techne or view top insider-selling stocks.

Which institutional investors are buying Bio-Techne stock?

TECH stock was bought by a variety of institutional investors in the last quarter, including Chevy Chase Trust Holdings Inc., Robeco Institutional Asset Management B.V., Private Advisor Group LLC, Obermeyer Wood Investment Counsel Lllp, Crossmark Global Holdings Inc., Pensionfund DSM Netherlands, BLB&B Advisors LLC, and Ritholtz Wealth Management.
View insider buying and selling activity for Bio-Techne or or view top insider-buying stocks.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $497.45.

How much money does Bio-Techne make?

Bio-Techne has a market capitalization of $19.44 billion and generates $931.03 million in revenue each year. The biotechnology company earns $140.41 million in net income (profit) each year or $5.73 on an earnings per share basis.

How many employees does Bio-Techne have?

Bio-Techne employs 2,300 workers across the globe.

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.

When was Bio-Techne founded?

Bio-Techne was founded in 1981.

What is Bio-Techne's official website?

The official website for Bio-Techne is www.bio-techne.com.

Where are Bio-Techne's headquarters?

Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at (612) 379-8854 or via email at [email protected].